We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Syndax Pharmaceuticals announced that its targeted cancer therapy, SNDX-5613, induced complete remission for certain advanced leukemia patients in an early-stage study. Read More
Novartis has released new data from a late-stage study showing that its multiple sclerosis (MS) drug Kesimpta (ofatumumab) reduced the risk of disease progression. Read More
Merck has decided to end research and development on MK-7110, an experimental oral drug for treatment of hospitalized coronavirus patients that had shown promise in a late-stage trial. Read More
People vaccinated with Pfizer/BioNTech’s double-dose COVID-19 vaccine will likely need to receive a booster shot within a year of full inoculation, as well as an annual shot, according to Pfizer CEO Albert Bourla. Read More
Those treated with the antibody combination who suffered from symptomatic infection generally saw their symptoms end in one week vs. three weeks. Read More